Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 15, 2018
Event: Entry into a Material Agreement to commence a rights offering to stockholders and certain participating warrant holders.
Key Financial Metrics and Offering Details
- Offering Size: Up to 35,714,285 units.
- Subscription Price: $0.70 per unit.
- Target Proceeds: Up to $25.0 million (subject to pro rata allocation if oversubscribed).
- Expected Net Proceeds: Approximately $23 million (after deducting commissions and expenses).
- Unit Composition: One share of common stock, 0.25 Series A Warrants, and 0.75 Series B Warrants.
- Warrant Terms:
- Series A: 12-month term, exercise price of $0.90.
- Series B: 30-month term, exercise price of $1.10.
- Dealer Manager Fees: 7.0% of proceeds plus $85,000 for legal expenses.
Material Changes and Agreements
The Company entered into a Dealer-Manager Agreement with Maxim Group LLC to act as the exclusive dealer-manager. Maxim will provide marketing assistance and solicit subscriptions but is not obligated to purchase any securities. The offering is subject to customary closing conditions, including the absence of a material adverse effect on the Company's business or financial position.
Outlook, Risks, and Unusual Items
- Subscription Period: February 15, 2018, through March 2, 2018 (5:00 PM ET), unless extended.
- Over-subscription: If demand exceeds the $25.0 million threshold, participation will be allocated on a pro rata basis.
- Indemnification: The Company agreed to indemnify Maxim and its affiliates against certain liabilities under the Securities Act of 1933.
- Financial Impact: The filing does not provide current revenue, profit, or cash flow data; it focuses solely on the capital raise mechanics.
Investor Verification Checklist
- Verify the final number of units sold and total gross proceeds raised.
- Confirm the actual net proceeds received after all offering expenses.
- Monitor the exercise rates of the Series A and Series B warrants over their respective terms.
- Review the Prospectus Supplement for any changes to the subscription period or offering size.
- Check for any material adverse effects on the Company's operations that might have triggered the closing conditions.